Ironwood Pharmaceuticals (IRWD) Accumulated Expenses (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Accumulated Expenses data on file, last reported at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 61.67% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (down 61.67% YoY), and the FY2025 full-year result was $4.4 million, down 69.5% from the prior year.
• Accumulated Expenses rose to $4.7 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $44.3 million in Q4 2023 to a low of $188000.0 in Q4 2022.
• A 5-year average of $14.1 million and a median of $12.3 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses sank 98.87% in 2022 and surged 23439.36% in 2023, its largest moves.
• Tracing IRWD's Accumulated Expenses over 5 years: stood at $188000.0 in 2022, then surged by 23439.36% to $44.3 million in 2023, then slumped by 67.13% to $14.5 million in 2024, then plunged by 69.5% to $4.4 million in 2025, then grew by 6.51% to $4.7 million in 2026.
• Business Quant data shows IRWD's Accumulated Expenses at $4.7 million in Q1 2026, $4.4 million in Q4 2025, and $7.5 million in Q3 2025.